stockportfolio.pro
Stocks / BCRX vs IMNM
BCRX vs IMNM
BioCryst Pharmaceuticals, Inc. and Immunome, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| BioCryst Pharmaceuticals, Inc. (BCRX) | Immunome, Inc. (IMNM) | |
|---|---|---|
| Market cap | $2.1B | $2.1B |
| Revenue (latest FY) | $874.84M | $6.94M |
| Net income (latest FY) | $263.86M | $-212.39M |
| Revenue growth (5y CAGR) | 117.9% | — |
| Net margin | 30.2% | -3060.0% |
| Return on equity | -221.4% | -33.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BCRX — free Open IMNM — freeFrequently asked questions
Which is bigger, BCRX or IMNM?
BioCryst Pharmaceuticals, Inc. is larger by market capitalization — $2.1B versus $2.1B.
Which grows faster, BCRX or IMNM?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.